InsidersTradesSigma
Follow the Viridian Therapeutics, Inc.\DE share price and the full directors' dealings record of the company, a listed equity based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Viridian Therapeutics, Inc.\DE has recorded 42 reports. Market capitalisation: €2.7bn. The latest transaction was filed on 19 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Meisner Lara. Every trade is free.
42
Insider Decl.
n/a
Thresholds
€66m
10 ops.
Buy Volume
€4m
8 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Viridian Therapeutics, Inc.\DE Strong Buy (bullish), based on 16 analysts. Average price target: US$36.63.
50Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 19 August 2026
Declarations42 total
14,212 shares@ US$24.50CommonSEC144:0001959173-26-006222
40,000 shares@ US$13.210.025% mcap100.0% of flowCommon StockSEC:0001193125-26-355735:0
2,031 shares@ US$30.19100.0% of flowCommon StockSEC:0001193125-26-099023:0
3,048 shares@ US$30.1942.9% of flowCommon StockSEC:0001193125-26-099014:0
7,408 shares@ US$30.1930.0% of flowCommon StockSEC:0001193125-26-099007:0
1,675 shares@ US$30.190.0025% mcap50.0% of flowCommon StockSEC:0001193125-26-099008:0
9,409 sharesCommon StockSEC:0001193125-26-092040:0
5,169 sharesCommon StockSEC:0001193125-26-092074:0
6,267 sharesCommon StockSEC:0001193125-26-092071:0
18,357 sharesCommon StockSEC:0001193125-26-092036:0
2,272 shares@ US$31.1658.2% of flowCommon StockSEC:0001193125-26-001097:0
454,545 shares@ US$22.0013.6% of flowCommon StockSEC:0001104659-25-102606:0
Canonical exit: 21 Jan 2026 (T+90)
1,600 shares@ US$7.800.0% of flowCommon StockSEC:0001104659-25-058580:0
5,000 shares@ US$23.41100.0% of flowCommon StockSEC:0000950170-24-110485:0
Canonical exit: 26 Dec 2024 (T+90)
21,400 shares@ US$23.33100.0% of flowCommon StockSEC:0000950170-24-110484:0
Canonical exit: 26 Dec 2024 (T+90)
1,600,000 shares@ US$18.7542.9% of flowCommon StockSEC:0001104659-24-100769:0
Canonical exit: 12 Dec 2024 (T+90)
5,859 sharesCommon StockSEC:0000950170-24-039599:0
476,190 shares@ US$21.0014.5% of flowCommon StockSEC:0000950170-24-007123:0
Canonical exit: 21 Apr 2024 (T+90)
2,269 shares@ US$23.034.2% of flowCommon StockSEC:0000899243-23-015998:0
1,875 shares@ US$14.002.1% of flowCommon StockSEC:0000899243-23-014615:0
4,000 shares@ US$25.369738.1% of flowCommon StockSEC:0000950170-23-012595:0
Canonical exit: 11 Jul 2023 (T+90)
5,500 shares@ US$29.149961.9% of flowCommon StockSEC:0000950170-23-007570:0
Canonical exit: 11 Jun 2023 (T+90)
29,971 shares@ US$29.0772.1% of flowCommon StockSEC:0000899243-23-007996:0
50,000 shares@ US$0.150.2% of flowCommon StockSEC:0000899243-23-004233:0
250,000 shares0Common StockSEC:0000899243-23-004238:0
25 of 42 declarations
关于 Viridian Therapeutics, Inc.\DE
Viridian Therapeutics, Inc. 是一家美国生物技术公司，在纳斯达克市场（美国）上市，股票代码为 VRDN。Viridian 总部位于马萨诸塞州沃尔瑟姆，专注于开发可能成为同类最佳的自身免疫和罕见疾病药物，其最先进和最具商业相关性的工作集中在甲状腺眼病 (TED) 上。该公司最初于 2010 年 1 月成立为特拉华州有限责任公司，后于 2014 年 6 月注册成立，并于 2021 年 1 月与 miRagen Therapeutics 合并后采用 Viridian Therapeutics 的名称。([sec.gov](https://www.sec.gov/Archives/edgar/data/1590750/000159075024000007/vrdn-20231231.htm?utm_source=openai)) Viridian 的商业模式围绕抗体发现和蛋白质工程构建。该公司并非为了追求全新的生物学而追求全新的生物学，而是针对临床验证的途径，在这些途径中，现有疗法存在有意义的未满足需求，旨在提高疗效、耐受性和便利性。这一框架在 TED 中尤为明显，TED 是一种自身免疫性疾病，可导致眼球突出、疼痛、复视和生活质量下降。Viridian 将其使命定位为改善自身免疫和罕见疾病患者的治疗选择，并反复强调差异化的临床活性和更便捷的给药方式是核心设计目标。([viridiantherapeutics.com](https://www.viridiantherapeutics.com/about/?utm_source=openai)) 该公司的主要资产是 veligrotug（前身为 VRDN-001），一种静脉注射抗 IGF-1R 抗体，以及 elegrobart（前身为 VRDN-003），一种皮下抗 IGF-1R 候选药物，旨在提供更便捷的给药方式。这两个项目都在活动性和慢性 TED 中产生了积极的 3 期数据。2025 年，Viridian 获得 FDA 对 veligrotug 的突破性疗法认定，提交了 BLA，并获得了优先审查，PDUFA 目标行动日期为 2026 年 6 月 30 日。2026 年，该公司还报告了 elegrobart 的 REVEAL-1 和 REVEAL-2 3 期研究的积极顶线数据，从而加强了更广泛的 TED 特许经营权的商业和临床案例。([investors.viridiantherapeutics.com](https://investors.viridiantherapeutics.com/news/news-details/2025/Viridian-Therapeutics-Receives-FDA-Breakthrough-Therapy-Designation-for-Veligrotug-for-the-Treatment-of-Thyroid-Eye-Disease-TED/default.aspx?utm_source=openai)) 从竞争角度来看，Viridian 试图通过临床效力、更少的输液以及（对于皮下版本）可能改善患者便利性和医生采纳率的组合来区分自己。管理层表示，目标是将 veligrotug 和 elegrobart 确立为 TED 的基础疗法，目前正在进行美国上市准备工作，欧洲备案策略也在推进中。除了 TED，产品线还包括早期项目，如 VRDN-006 和 VRDN-008，以及其他以自身免疫为重点的资产，这表明 TED 是第一个商业平台，而不是该公司唯一的长期机会。([investors.viridiantherapeutics.com](https://investors.viridiantherapeutics.com/news/news-details/2026/Viridian-Therapeutics-Highlights-Recent-Progress-and-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results?utm_source=openai)) 对于投资者而言，Viridian 最好被视为一家催化剂驱动的生物技术公司，具有重大的执行风险，但如果达到监管和上市里程碑，则具有巨大的上行空间。最近的头条新闻集中在 veligrotug 的监管路径、elegrobart 的积极读数以及强化的资产负债表上，所有这些都支持该公司从纯研发向潜在商业化的转型。([investors.viridiantherapeutics.com](https://investors.viridiantherapeutics.com/news/news-details/2026/Viridian-Therapeutics-Announces-Positive-Topline-Results-from-Elegrobart-Phase-3-REVEAL1-Clinical-Trial-in-Active-Thyroid-Eye-Disease/default.aspx?utm_source=openai))
